Clinical trials: Chronic Obstruct Airways Disease
Chronic Obstructive Pulmonary Disease
Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD)
This study compared the 14-day bronchodilator efficacy of indacaterol with that of placebo and salmeterol.
- Trial name
- NCT01089127
- Testing
- Indacaterol, Salmeterol 50 μg
- Where
- 69 sites in United States
- Volunteers
- 552 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
Real-World Effectiveness of a Triple Combination BDP/FF/GB in a Single Pressurised Metered Dose Inhaler in COPD Patients (TRIPHY)
The purpose of the study is to evaluate Real-World Effectiveness of a Triple Combination Beclometasone Diproprionate/Formoterol Fumarate/Glycopyrronium Bromide (BDP/FF/GB) in a Single Pressurised Metered Dose Inhaler (Trimbow®…
- Trial name
- TRIPHY (NCT06480890)
- Where
- 19 sites in China
- Volunteers
- 362 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Pulmonary Disease, Chronic Obstructive
Postmarketing Surveillance Study of Atrovent® Inhalation Solution in Chronic Obstructive Pulmonary Disease
To obtain further information on the tolerability and efficacy of Atrovent® 500µg/2ml inhalation solution in the treatment of Chronic Obstructive Pulmonary Disease under conditions of daily practice
- Trial name
- NCT02238197
- Testing
- Atrovent® Inhalation Solution
- Volunteers
- 477 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Efficacy, Pharmacokinetics and Safety Comparison of Salmeterol Inhalation Powder Administered Via the HandiHaler® 2 and Serevent® Diskus® in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The primary objective of this trial was to establish non-inferiority of lung function response to 25 μg salmeterol, administered as the xinafoate salt, in an inhalation powder delivered from hard polyethylene (PE) capsules via…
- Trial name
- NCT02242227
- Testing
- Salmeterol xinafoate, Serevent® Diskus®
- Volunteers
- 111 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Factors Determining Quality of Life Related to Respiratory Status According to Gender of Chronic Obstructive Pulmonary Disease (COPD) Patients
The purpose of this study is to evaluate with sufficient precision and according to gender the determining independent factors of quality of life related to respiratory status of patient with moderate to severe COPD.
- Trial name
- VITALITE (NCT01007734)
- Where
- 178 sites in France
- Volunteers
- 449 people
- Sponsor
- AstraZeneca
COPD (Chronic Obstructive Pulmonary Disease)
A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius)
This study is trying to identify the right dose of a long-acting medicine called WIN378 for people with moderate - severe chronic obstructive pulmonary disease (COPD).
- Trial name
- Sirius (NCT07646587)
- Testing
- WIN378
- Where
- 32 sites in United States, Argentina
- Volunteers
- 105 people
- Sponsor
- Windward Bio
Pulmonary Disease, Chronic Obstructive
A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
To evaluate the efficacy and safety of TQC3721 Suspension for Inhalation in patients with moderate to severe Chronic obstructive pulmonary disease (COPD)
- Trial name
- NCT06527144
- Testing
- 3mg TQC3721 Suspension for Inhalation, 6mg TQC3721 Suspension for Inhalation
- Where
- 28 sites in China
- Volunteers
- 240 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Chronic Obstructive Pulmonary Disease (COPD)
Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)
This is a multicenter, randomized, double-blind, parallel group, chronic-dosing (24 weeks), placebo-controlled study to assess the efficacy and safety of Glycopyrrolate (GP and Formoterol Fumarate (FF) combination metered-dose…
- Trial name
- NCT01854658
- Testing
- GFF MDI (PT003), GP MDI (PT001), FF MDI (PT005)
- Where
- 113 sites in United States
- Volunteers
- 1,615 people
- Sponsor
- Pearl Therapeutics, Inc.
Pulmonary Disease, Chronic Obstructive
Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
Direct comparison studies of the tiotropium HandiHaler® 18 µg and Respimat® 5 µg formulations have been limited to 4-week crossover studies.
- Trial name
- NCT01126437
- Testing
- tiotropium 18 mcg, tiotropium 1.25 mcg (2 actuations/day), tiotropium 2.5 mcg (2 actuations/day)
- Where
- 1,191 sites in United States, Argentina and 49 more
- Volunteers
- 17,183 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Assessment of Health-status of Patients With Chronic Obstructive Pulmonary Disease (COPD) on Maintenance Therapy With Spiriva HH Measured by COPD Assessment Test (CAT) Test
To evaluate the early (3-month) impact of the long-acting anticholinergic Spiriva HH maintenance treatment on the COPD symptoms using the novel COPD Assessment test (CAT) in the real life setting of COPD patients, previously…
- Trial name
- NCT01644734
- Testing
- Spiriva HandiHaler
- Where
- 247 sites in Poland
- Volunteers
- 1,328 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD
This is a Phase 2 study in patients with chronic obstructive pulmonary disease (COPD) to assess the efficacy, pharmacodynamics (PD), pharmacokinetics (PK), and safety of two dose levels of CSJ117 in comparison to placebo.
- Trial name
- NCT04882124
- Testing
- CSJ117
- Where
- 15 sites in United States, Australia and 4 more
- Volunteers
- 38 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
The Use of High Frequency Oscillations With NIV in Hypercapnic COPD Participants
Chronic Obstructive Pulmonary Disease (COPD) is a major cause of chronic morbidity and mortality throughout the world, being the fourth leading cause of death in the world.
- Trial name
- NCT02680639
- Testing
- BiPAP Synchrony ventilator
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Philips Respironics
COPD
Efficacy and Safety of AQX-1125 in Unstable COPD
The primary objective of this study is to evaluate the effect of 12 weeks of treatment with once daily administration of AQX-1125 compared to placebo in subjects following exacerbations of Chronic Obstructive Pulmonary Disease…
- Trial name
- FLAGSHIP (NCT01954628)
- Testing
- AQX-1125
- Where
- 8 sites in United States, Australia and 6 more
- Volunteers
- 400 people
- Sponsor
- Aquinox Pharmaceuticals (Canada) Inc.
Pulmonary Disease, Chronic Obstructive
A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease
The study is intended to characterize the lung function profile of BI1744 in Chronic Obstructive Pulmonary Disease (COPD) patients where patients will perform pulmonary function tests at regular intervals for 24 hours at the end…
- Trial name
- NCT01040728
- Testing
- Olodaterol (BI1744) Low, Olodaterol (BI1744) High, Tiotropium 18 mcg
- Where
- 12 sites in United States, Germany and 2 more
- Volunteers
- 122 people
- Sponsor
- Boehringer Ingelheim
Asthma, Pulmonary Disease, Chronic Obstructive
A Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
The purpose of this study is to characterize the clinical, physiologic, and molecular profiles of healthy participants, participants with mild, moderate, and severe asthma; and participants with moderate to severe Chronic…
- Trial name
- NCT01274507
- Testing
- Medical tests
- Where
- 21 sites in United States, Canada and 6 more
- Volunteers
- 328 people
- Sponsor
- Janssen Research & Development, LLC
Pulmonary Disease, Chronic Obstructive
Vahelva Respimat Regulatory Post-marketing Surveillance in Korean Patients With Chronic Obstructive Pulmonary Disease
To monitor the safety profile and effectiveness of Vahelva Respimat in Korean patients with COPD in a routine clinical practice setting
- Trial name
- NCT02864407
- Testing
- Vahelva® Respimat® (Tiotropium + Olodaterol fixed dose combination)
- Where
- South Korea
- Volunteers
- 3,223 people
- Sponsor
- Boehringer Ingelheim
Obstructive Sleep Apnea, Obesity Hypoventilation Syndrome (OHS)
Evaluation of Auto-EPAP for Management of Upper Airway Obstruction During Non-Invasive Ventilation
To evaluate the safety and effectiveness of the Automatic Expiratory Positive Airway Pressure (Auto-EPAP) feature versus manual expiratory positive airway pressure (EPAP) in the Vivo 45 LS Ventilator.
- Conditions
- Obstructive Sleep Apnea, Obesity Hypoventilation Syndrome (OHS), Chronic Obstructive Pulmonary Disease (COPD), Neuromuscular Diseases (NMD)
- Trial name
- Vivo NOVA (NCT06560411)
- Testing
- Non-Invasive Ventilation
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- Breas Medical, Inc.
Pulmonary Disease, Chronic Obstructive
Triple Therapy in Chronic Obstructive Pulmonary Disease (COPD) Participants
TETRIS is a multi-center, prospective observational cohort study. It will include participants with COPD who are on an existing combined treatment of long-acting muscarinic antagonist (LAMA), long-acting beta 2 agonists (LABA)…
- Trial name
- TETRIS (NCT04657211)
- Testing
- Prospective observational cohort study
- Where
- Germany
- Volunteers
- 1,212 people
- Sponsor
- GlaxoSmithKline
Asthma
GSK2190915A - Bioavailability Study
GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor that reduces inflammation in cells. This study will evaluate three capsule and two tablet formulations to select the optimal formulation for further…
- Trial name
- NCT02224521
- Testing
- GSK2190915 Solution., GSK2190915 Granule Capsule (A), GSK2190915 Semi-solid Lipid Capsule (B)
- Where
- United Kingdom
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With Benralizumab
The objective of this study is to collect empirical data that elucidates the clinical profile and therapeutic efficacy of benralizumab among the patients aged 12 years and above, with severe eosinophilic asthma.
- Trial name
- SPEED (NCT06862206)
- Testing
- benralizumab
- Where
- 36 sites in China
- Volunteers
- 1,000 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.